Recent Investment Analysts’ Ratings Updates for Moderna (MRNA)

Moderna (NASDAQ: MRNA) has recently received a number of price target changes and ratings updates:

• 9/19/2024 – Moderna had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada. They now have a $75.00 price target on the stock.
• 9/17/2024 – Moderna had its price target lowered by analysts at Leerink Partners from $60.00 to $48.00. They now have an “underperform” rating on the stock.
• 9/16/2024 – Moderna had its price target lowered by analysts at Barclays PLC from $155.00 to $125.00. They now have an “overweight” rating on the stock.
• 9/16/2024 – Moderna had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $178.00 to $139.00. They now have a “buy” rating on the stock.
• 9/13/2024 – Moderna was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating. They now have a $70.00 price target on the stock, down previously from $88.00.
• 9/13/2024 – Moderna had its price target lowered by analysts at Royal Bank of Canada from $90.00 to $75.00. They now have a “sector perform” rating on the stock.
• 9/13/2024 – Moderna had its price target lowered by analysts at Piper Sandler from $157.00 to $115.00. They now have an “overweight” rating on the stock.
• 9/13/2024 – Moderna had its price target lowered by analysts at Bank of America Co. from $130.00 to $110.00. They now have a “neutral” rating on the stock.
• 9/13/2024 – Moderna was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
• 9/13/2024 – Moderna had its price target lowered by analysts at TD Cowen from $70.00 to $60.00. They now have a “hold” rating on the stock.
• 9/13/2024 – Moderna had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 9/13/2024 – Moderna was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $65.00 price target on the stock, down previously from $120.00.
• 8/28/2024 – Moderna was upgraded by analysts at Hsbc Global Res from a “moderate sell” rating to a “hold” rating.
• 8/28/2024 – Moderna was upgraded by analysts at HSBC Holdings plc from a “reduce” rating to a “hold” rating. They now have a $82.00 price target on the stock.
• 8/15/2024 – Moderna had its price target lowered by analysts at JPMorgan Chase & Co. from $96.00 to $88.00. They now have a “neutral” rating on the stock.
• 8/7/2024 – Moderna was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating. They now have a $80.00 price target on the stock, down previously from $85.00.
• 8/5/2024 – Moderna was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $90.00 price target on the stock, down previously from $125.00.
• 8/2/2024 – Moderna had its price target lowered by analysts at Barclays PLC from $168.00 to $155.00. They now have an “overweight” rating on the stock.
• 8/2/2024 – Moderna had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $157.00 price target on the stock, down previously from $214.00.
• 8/2/2024 – Moderna had its price target lowered by analysts at Royal Bank of Canada from $160.00 to $125.00. They now have an “outperform” rating on the stock.
• 8/2/2024 – Moderna had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $204.00 to $178.00. They now have a “buy” rating on the stock.
• 8/1/2024 – Moderna had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

Moderna Stock Up 3.6 %

NASDAQ:MRNA traded up $2.30 during midday trading on Friday, reaching $66.23. 2,554,483 shares of the stock traded hands, compared to its average volume of 4,310,323. The business has a 50-day moving average of $85.34 and a two-hundred day moving average of $109.78. The stock has a market capitalization of $25.38 billion, a PE ratio of -4.23 and a beta of 1.67. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter last year, the company posted ($3.62) earnings per share. The business’s quarterly revenue was down 29.9% on a year-over-year basis. On average, equities analysts forecast that Moderna, Inc. will post -9.86 earnings per share for the current fiscal year.

Insider Activity at Moderna

In related news, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares in the company, valued at $174,665,819.68. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares in the company, valued at $682,754. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Stephen Hoge sold 15,000 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now owns 1,442,089 shares in the company, valued at approximately $174,665,819.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,158 shares of company stock worth $9,259,012. 15.70% of the stock is owned by company insiders.

Institutional Trading of Moderna

Several institutional investors have recently modified their holdings of MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Moderna in the second quarter valued at about $26,000. Cedar Wealth Management LLC lifted its stake in shares of Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares in the last quarter. Westside Investment Management Inc. purchased a new position in shares of Moderna in the first quarter worth about $32,000. Family Firm Inc. purchased a new position in shares of Moderna in the second quarter worth about $33,000. Finally, Rise Advisors LLC lifted its stake in shares of Moderna by 953.3% in the first quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after buying an additional 286 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.